| 5/9/2021 |
NeoGenomics (NASDAQ:NEO) Issues Quarterly Earnings Results |
Mayfield Recorder |
NeoGenomics (NASDAQ:NEO) Issues Quarterly Earnings Results Posted by Cindy Kellogue on May 8th, 2021NeoGenomics (NASDAQ:NEO) issued its quarterly earnings data on Wednesday. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by ($0.05), Briefing.com reports. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. The company had ... |
| 5/8/2021 |
Congressman Cohen Announces Grants to St. Jude Children's Research Hospital and UTHSC |
US House of Representatives |
... system. The grant to UTHSC, for $154,000, is for genetic research involving mice.Congressman Cohen made the following statement:“I’m always pleased to see the National Institutes of Health investing in our premier medical research institutions. This funding will advance our understanding of the nervous system and improve lives.” ... |
| 5/8/2021 |
NeoGenomics (NASDAQ:NEO) Releases Quarterly Earnings Results | Daily Political |
Daily Political |
NeoGenomics (NASDAQ:NEO) announced its earnings results on Wednesday. The medical research company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.05), Briefing.com reports. The company had revenue of $115.30 million during the quarter, compared to analysts’ expectations of $112.17 million. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. The company’s revenue for ... |
| 5/8/2021 |
NeoGenomics (NASDAQ:NEO) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS |
zolmax.com |
NeoGenomics (NASDAQ:NEO) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS Posted by Bonnie Powley on May 8th, 2021 TweetNeoGenomics (NASDAQ:NEO) issued its earnings results on Wednesday. The medical research company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by ($0.05), Briefing.com reports. NeoGenomics had a positive return on equity of 0.71% and a negative net margin of ... |
| 5/8/2021 |
NeoGenomics (NASDAQ:NEO) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS - Transcript Daily |
transcriptdaily.com |
NeoGenomics (NASDAQ:NEO) issued its earnings results on Wednesday. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.05), Briefing.com reports. The company had revenue of $115.30 million during the quarter, compared to analyst estimates of $112.17 million. NeoGenomics had a positive return on equity of 0.71% and a negative net margin of 1.16%. The firm’s revenue ... |
| 5/8/2021 |
NeoGenomics (NASDAQ:NEO) Issues Earnings Results - Stock Observer |
thestockobserver.com |
NeoGenomics (NASDAQ:NEO) announced its quarterly earnings data on Wednesday. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by ($0.05), Briefing.com reports. The firm had revenue of $115.30 million for the quarter, compared to analyst estimates of $112.17 million. NeoGenomics had a negative net margin of 1.16% and a positive return on equity of 0.71%. The ... |
| 5/8/2021 |
NeoGenomics (NASDAQ:NEO) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS |
slatersentinel.com |
NeoGenomics (NASDAQ:NEO) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS Posted by Jay Halladay on May 8th, 2021NeoGenomics (NASDAQ:NEO) issued its quarterly earnings data on Wednesday. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.05), Briefing.com reports. The company had revenue of $115.30 million during the quarter, compared to analysts’ expectations of $112.17 ... |
| 5/8/2021 |
NeoGenomics (NASDAQ:NEO) Announces Earnings Results, Misses Expectations By $0.05 EPS |
Mayfield Recorder |
NeoGenomics (NASDAQ:NEO) Announces Earnings Results, Misses Expectations By $0.05 EPS Posted by Sean Solarzano on May 8th, 2021NeoGenomics (NASDAQ:NEO) released its quarterly earnings results on Wednesday. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.05), Briefing.com reports. The business had revenue of $115.30 million for the quarter, compared to analysts’ expectations of ... |
| 5/8/2021 |
Comerica Bank Decreases Position in IQVIA Holdings Inc. (NYSE:IQV) |
baseballnewssource.com |
... Holdings Inc. (NYSE:IQV) by 2.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,103 shares of the medical research company’s stock after selling 890 shares during the period. Comerica Bank’s holdings in IQVIA were worth $7,922,000 as of its most recent filing with the Securities and Exchange Commission.A number of ... |
| 5/8/2021 |
IQVIA Holdings Inc. (NYSE:IQV) Stake Raised by Handelsbanken Fonder AB - American Banking News |
American Banking News |
... IQVIA Holdings Inc. (NYSE:IQV) by 2.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 45,731 shares of the medical research company’s stock after acquiring an additional 1,200 shares during the quarter. Handelsbanken Fonder AB’s holdings in IQVIA were worth $8,832,000 as of its most recent SEC filing.A number of other institutional ... |
| 5/8/2021 |
Handelsbanken Fonder AB Acquires 1,200 Shares of IQVIA Holdings Inc. (NYSE:IQV) |
slatersentinel.com |
... by Sam Norman on May 8th, 2021Handelsbanken Fonder AB grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.7% during the 1st quarter, HoldingsChannel reports. The firm owned 45,731 shares of the medical research company’s stock after purchasing an additional 1,200 shares during the quarter. Handelsbanken Fonder AB’s holdings in IQVIA were worth $8,832,000 at the end of the most recent reporting period.Several other institutional ... |
| 5/8/2021 |
IQVIA Holdings Inc. (NYSE:IQV) Stake Raised by Handelsbanken Fonder AB |
Mayfield Recorder |
... IQVIA Holdings Inc. (NYSE:IQV) by 2.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 45,731 shares of the medical research company’s stock after acquiring an additional 1,200 shares during the quarter. Handelsbanken Fonder AB’s holdings in IQVIA were worth $8,832,000 as of its most recent SEC filing.A number of other institutional ... |
| 5/8/2021 |
Klingenstein Fields & Co. LP Acquires Shares of 1,321 IQVIA Holdings Inc. (NYSE:IQV) | Daily Political |
Daily Political |
... new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,321 shares of the medical research company’s stock, valued at approximately $255,000.Several other hedge funds also recently made changes to their positions in the company. Pinnacle Wealth Planning Services Inc. grew its stake in shares of IQVIA by ... |
| 5/8/2021 |
Klingenstein Fields & Co. LP Invests $255,000 in IQVIA Holdings Inc. (NYSE:IQV) |
zolmax.com |
... position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,321 shares of the medical research company’s stock, valued at approximately $255,000.A number of other institutional investors have also recently added to or reduced their stakes in the stock. Pinnacle Wealth Planning Services Inc. boosted its holdings in ... |
| 5/8/2021 |
Q2 2021 EPS Estimates for Invitae Co. Decreased by Analyst (NYSE:NVTA) - Ticker Report |
Ticker Report |
Invitae Co. (NYSE:NVTA) – Investment analysts at Oppenheimer decreased their Q2 2021 earnings per share estimates for shares of Invitae in a research report issued on Tuesday, May 4th. Oppenheimer analyst K. Degeeter now forecasts that the medical research company will post earnings of ($0.82) per share for the quarter, down from their prior estimate of ($0.64). Oppenheimer has a “Outperform” rating and a $48.00 price target on ... |
| 5/8/2021 |
Q2 2021 EPS Estimates for Invitae Co. Decreased by Analyst (NYSE:NVTA) | Daily Political |
Daily Political |
Invitae Co. (NYSE:NVTA) – Oppenheimer dropped their Q2 2021 earnings estimates for shares of Invitae in a report released on Tuesday, May 4th. Oppenheimer analyst K. Degeeter now expects that the medical research company will post earnings per share of ($0.82) for the quarter, down from their prior estimate of ($0.64). Oppenheimer has a “Outperform” rating and a $48.00 price target on the stock. Oppenheimer also issued estimates ... |
| 5/8/2021 |
SVB Leerink Research Analysts Lower Earnings Estimates for Invitae Co. (NYSE:NVTA) - WKRB News |
wkrb13.com |
Invitae Co. (NYSE:NVTA) – Stock analysts at SVB Leerink dropped their Q2 2021 earnings estimates for shares of Invitae in a note issued to investors on Tuesday, May 4th. SVB Leerink analyst P. Souda now anticipates that the medical research company will post earnings of ($0.78) per share for the quarter, down from their prior forecast of ($0.55). SVB Leerink currently has a “Outperform” rating and a $50.00 ... |
| 5/8/2021 |
Natera (NASDAQ:NTRA) Shares Gap Up Following Better-Than-Expected Earnings |
The Markets Daily |
... Friday following a stronger than expected earnings report. The stock had previously closed at $96.31, but opened at $101.44. Natera shares last traded at $103.30, with a volume of 7,136 shares trading hands.The medical research company reported ($0.74) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.05) by $0.31. The business had revenue of $152.32 million during the quarter, compared to analyst estimates of $114.42 ... |
| 5/8/2021 |
Charles River Laboratories International, Inc. to Post Q2 2021 Earnings of $2.32 Per Share, Jefferies Financial Group Forecasts (NYSE:CRL) - WKRB News |
wkrb13.com |
... Group raised their Q2 2021 earnings estimates for shares of Charles River Laboratories International in a note issued to investors on Wednesday, May 5th. Jefferies Financial Group analyst D. Windley now anticipates that the medical research company will post earnings of $2.32 per share for the quarter, up from their prior estimate of $2.21. Jefferies Financial Group also issued estimates for Charles River Laboratories International’s FY2021 earnings at $9.89 ... |
| 5/8/2021 |
Natera (NASDAQ:NTRA) Shares Gap Up After Strong Earnings - Dakota Financial News |
Dakota Financial News |
... Friday following a better than expected earnings announcement. The stock had previously closed at $96.31, but opened at $101.44. Natera shares last traded at $103.30, with a volume of 7,136 shares trading hands.The medical research company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.31. The business had revenue of $152.32 million for the quarter, compared to analyst estimates of ... |